Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents

      

This page is updated frequently with new Receptor-related patent applications.




Date/App# patent app List of recent Receptor-related patents
08/18/16
20160239993 
 System and  enabling multiple-state avatars patent thumbnailSystem and enabling multiple-state avatars
A method for rendering a virtual world avatar of a computerized system is disclosed. The method comprises defining a plurality of receptor points located on the virtual world avatar, wherein the plurality of receptor points is associated with at least one object that moves between the plurality of receptor points based upon at least one predetermined trigger, changing a state of at least one of the plurality of receptor points from a first state to a second state based upon a measurable quantity and a predetermined threshold to update the associated at least one object, and in response to the measurable quantity no longer satisfying the predetermined threshold, reverting the state of the at least one of the plurality of receptor points from the second state back to the first state..
International Business Machines Corporation


08/18/16
20160238955 
 Electrophotographic photoreceptor, process cartridge, and image forming apparatus patent thumbnailElectrophotographic photoreceptor, process cartridge, and image forming apparatus
Wherein x2 represents an oxygen atom or ═c(cn)2; r21 to r27 independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an aryl group or an aralkyl group; and r28 represents an alkylene group having 4 to 20 carbon atoms or the like.. .

08/18/16
20160238613 
 Antigen receptor screening assay patent thumbnailAntigen receptor screening assay
The present invention provides methods for the identification of an antigen receptor (e.g., an antibody) that specifically binds to an antigen of interest. Generally, this involves contacting a plurality of antigen receptor-expressing cells with an antigen of interest; measuring the level of activated adhesion molecules on the surface of the antigen receptor-expressing cells; and, identifying from the plurality of antigen receptor-expressing cells an antigen receptor-expressing cell that exhibits an increased amount of activated adhesion molecules on the cell surface..
X-body, Inc.


08/18/16
20160237498 
 Prediction and treatment of heart failure patent thumbnailPrediction and treatment of heart failure
Chronic activation of the β-adrenergic receptor (β-ar) can have deleterious effects on the heart, and animal models over-expressing the β-ar develop heart failure. In the classical β-ar pathway, activation of the receptor results in increased cyclic amp(camp) levels.
The Regents Of The University Of Colorado, A Body Corporate


08/18/16
20160237437 
 Toll-like receptor 9 antagonist and methods of use thereof patent thumbnailToll-like receptor 9 antagonist and methods of use thereof
The invention provides antagonist of tlr9 and methods of use thereof. These compounds inhibit or suppress tlr9-mediated signaling.
Idera Pharmaceuticals, Inc.


08/18/16
20160237407 
 Universal donor chimeric antigen receptor cells patent thumbnailUniversal donor chimeric antigen receptor cells
Disclosed are allogeneic cells useful for the treatment of cancer in a universal donor, off the shelf, manner. In one embodiment of the invention cord blood derived t cell progenitors are matured with anti-cd3 and anti-cd28, interleukin-7 and transfected with a construct encoding a chimeric antigen receptor (car) targeting a tumor antigen or a tumor endothelial associated antigen on the antigen binding domain.
Batu Biologics, Inc.


08/18/16
20160237169 
 Binding moieties based on shark ignar domains patent thumbnailBinding moieties based on shark ignar domains
The present invention relates to immunoglobulin new antigen receptors (ignars) from fish and uses thereof. In particular, the present invention relates to modified ignar variable domains and to domains from members of the immunoglobulin superfamily that have been modified to include structural features derived from ignar variable domains..
Adalta Pty Ltd


08/18/16
20160237162 
 Binding molecules specific for her3 and uses thereof patent thumbnailBinding molecules specific for her3 and uses thereof
Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the her3 receptor and inhibit various her3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with her3 mediated signal transduction..
Medimmune, Llc


08/18/16
20160237146 
 Methods of preventing or reducing photoreceptor cell death patent thumbnailMethods of preventing or reducing photoreceptor cell death
The invention provides compositions and methods for preventing or reducing photoreceptor cell death. The invention further provides compositions and methods for treating, preventing, or alleviating symptoms of retinal detachment..
Massachusetts Eye And Ear Infirmary


08/18/16
20160237139 
 Chimeric antigen receptor patent thumbnailChimeric antigen receptor
The present invention provides a chimeric antigen receptor (car) comprising: (i) a b cell maturation antigen (bcma)-binding domain which comprises at least part of a proliferation-inducing ligand (april); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular t cell signaling domain. The invention also provides the use of such a t-cell expressing such a car in the treatment of plasma-cell mediated diseases, such as multiple myeloma..
Ucl Business Plc


08/18/16
20160237138 

Polypeptides and methods for modulating d1-d2 dopamine receptor interaction and function


The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal d1-d2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from d1-d2 coupling and/or activation.
Centre For Addiction And Mental Health


08/18/16
20160237135 

Interleukin-4 receptor-binding fusion proteins and uses thereof


The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptotic bcl-2 family member protein moiety..
Medicenna Therapeutics Pte Ltd


08/18/16
20160237133 

Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use


The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein. Such fgf2/fgf1 chimeras can further include a fibroblast growth factor receptor (fgfr) 1c-binding protein, a β-klotho-binding protein, or both.
Salk Institute For Biological Studies


08/18/16
20160237130 

Apelin fusion proteins and uses thereof


The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.


08/18/16
20160237081 

Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mglur2 receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


08/18/16
20160237072 

Oxazolidinones as modulators of mglur5


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mglur5 receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


08/18/16
20160237065 

Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics


Compounds that are agonists of the mcir receptor and that exhibit reduced toxicity relative to other compounds of the same class are described. These compounds can have the general formula (i) wherein: r1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; r2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of general formula (i).
Galderma Research & Development


08/18/16
20160237061 

Organic compounds


The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer..
Intra-cellular Therapies, Inc.


08/18/16
20160237055 

Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists


The present invention relates to compounds of formula (i), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where r1 and r2 are, independently, hydrogen, halogen, c1_3 alkyl or c1-3alkoxy; r3 is phenyl optionally substituted by r4 and r5 which are, independently hydrogen, halogen, c1-3 alkyl, c1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, n,n-dic1-3alkyl-amide, carboc1-3 alkoxy or c1-3alkylsulphone groups; r3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.. .
Polfarmex S.a.


08/18/16
20160237052 

Histamine-3 receptor antagonists


The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i; and a method of treatment of a disorder or condition selected from the list consisting of acute myocardial infarction; memory processes disorders; dementia; cognition disorders such as alzheimer's disease; attention deficit disorder (add); attention-deficit hyperactivity disorder (adhd); cancers such as cutaneous carcinoma, medullary thyroid carcinoma and melanoma; meniere's disease; gastrointestinal disorders; inflammation; migraine; motion sickness; obesity; pain; septic shock; respiratory disorders (including allergic rhinitis, nasal congestion and allergic congestion) in a mammal, including a human, that may be effected by administering to said mammal a pharmacologically effective amount of a compound of formula i, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.. .
Medisynergics, Llc


08/18/16
20160237036 

Azacyclic compounds


Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment..
Acadia Pharmaceuticals Inc.


08/18/16
20160237034 

Method for producing pyrrole derivative, and intermediate thereof


The present invention provides a method for producing an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, and an intermediate thereof. A method for producing an atropisomer of a pyrrole derivative using a compound represented by (b) [wherein r1 represents a c1-c4 alkyl group, and r2 represents a 2-hydroxyethyl group or a carboxymethyl group] as a production intermediate..
Daiichi Sankyo Company, Limited


08/18/16
20160235871 

Spect radionuclide-labeled trimeric cycle rgd peptide, preparation method thereof and imaging method thereof


The disclosure is related to a chemical structure, a preparation and an imaging method of a tumor imaging tracer, especially to a spect radionuclide-labeled trimeric cyclic rgd peptide: 99mtc-4p-rgd3, which functions as a ligand to be combined with integrin αvβ3 receptor in tumor for tumor imaging. The preparation includes linking hynic-osu with 4p-rgd3 to form hynic-4p-rgd3 and then chelating hynic with 99mtc to create 99mtc-4p-rgd3.
Bailing Cloud Biomedical Technologies Innovation


08/18/16
20160235869 

Derivatives of dibenzothiophene imaging of alpha-7 nicotinic acetylcholine receptors


The presently disclosed subject matter provides non-invasive methods for imaging, quantifying α7 nicotinic cholinergic receptors, and diagnosing a disease or condition associated with α7-nachrs. Methods for preparing radiolabeled derivatives of dibenzothiophene and compounds provided thereof also are provided..
The Johns Hopkins University


08/18/16
20160235844 

Methods of treating neuroendocrine tumors using frizzled-binding agents


Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a wnt antagonist.
Oncomed Pharmaceuticals, Inc.


08/18/16
20160235832 

Compositions and the use of fibrinogen binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery


The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, c3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.. .
University Medical Center Utrecht, The Netherlands


08/18/16
20160235819 

Methods of inducing melanogenesis in a subject


Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-msh analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors..
Clinuvel Pharmaceuticals Limited


08/18/16
20160235814 

Soluble fc gamma receptor for treatment of autoimmune bullous diseases


The invention generally relates to the field of biotechnology and medicine. It provides an agent, a pharmaceutical composition and a kit for treatment of autoimmune bullous diseases (amdb).
Suppremoi Gmbh


08/18/16
20160235807 

Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines


This invention provides a method to prevent, control, and/or treat an inflammatory disease or disorder by administering at least one agonist of guanalyte cyclase receptor, or pharmaceutical compositions thereof, either alone or either concurrently or sequentially with another compound or an active agent used to treat the disease or disorder, and/or with an inhibitor of cgmp-dependent phosphodieasterases.. .
Synergy Pharmaceuticals, Inc.


08/18/16
20160235787 

Epitope spreading associated with car t-cells


The present invention relates to compositions and methods for inducing epitope spreading by administering to a mammal an effective amount of a cell genetically modified to express a chimeric antigen receptor (car). The invention also relates to identification of antigens and antibodies involved in the epitope spreading associated with car t cells..
The Trustees Of The University Of Pennsylvania


08/18/16
20160235770 

Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid


Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin d analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(s)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(s)-2-methylene-1α,25-dihydroxyvitamin d3, 2-methylene-1α,25-dihydroxy-(17e)-17(20)-dehydro-19-nor-vitamin d3, 2-methylene-19-nor-(24r)-1α,25-dihydroxyvitamin d2, 2-methylene-(20r,25s)-19,26-dinor-1α,25-dihydroxyvitamin d3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20r)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20s)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20s)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20s)-1α-hydroxyvitamin d3, 2-methylene-18,19-dinor-(20s)-1α,25-dihydroxyvitamin d3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof.
Wisconsin Alumni Research Foundation


08/18/16
20160235763 

Use of redd1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists


Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (gr) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (gr) agonist and administering to the patient in need thereof a redd1 inhibitor that inhibits expression or activity of redd1, wherein the redd1 inhibitor is administered before, concurrently with, or after the gr agonist is administered..
Northwestern University


08/18/16
20160235762 

7-aminocephalosporanic acid derivative as inhibitor of il-15 and il-2 activity


The invention relates to 7-zminocephalosporanic acid derivative, cefazolin, for use as the inhibitor of il-15 and il-2 receptors in the prevention and treatment of il-15 and il-2 overproduction related diseases.. .
Warszawski Uniwersytet Medyczny


08/18/16
20160235759 

Kappa opioid receptor compounds


The invention is directed to a method of treatment for chronic pain, the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula i, or a pharmaceutically acceptable salt thereof.. .
Medisynergics, Llc


08/18/16
20160235742 

Spray dry formulations


Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (rtk) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of rtks associated with vascular and pulmonary disorders..

08/18/16
20160235734 

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity


Compounds of formula i, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.. .
Chiesi Farmaceutici S.p.a.


08/18/16
20160235732 

Methods and compositions for reduction of side effects of therapeutic treatments


The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment..
Parkinson's Institute


08/18/16
20160235727 

Novel pyrrolidine derived beta 3 adrenergic receptor agonists


The present invention provides compounds of formula (i), pharmaceutical compositions thereof, and method of us ing the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.. .
Merck Sharp & Dohme Corp.


08/18/16
20160235714 

Enzalutamide in combination with afuresertib for the treatment of cancer


A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt thereof, and an akt inhibiting compound, for example: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or akt inhibition is beneficial, e.g., cancer.. .
Novartis Ag


08/18/16
20160235712 

Cancer treatment method


Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (tpo) receptor agonist to such mammal, suitably a human.. .
Novartis Ag


08/18/16
20160235711 

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators


The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. .
Allergan, Inc.


08/18/16
20160235706 

Indanyloxydihydrobenzofuranylacetic acids


Wherein the groups (het)ar and r1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the gpr40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..

08/11/16
20160231867 

Coordinate input apparatus, control method thereof, and non-transitory computer-readable storage medium


A coordinate input apparatus detects a specified position in a coordinate-input effective area using a light projector that projects light onto a coordinate input surface and a plurality of light receptors that receive the light projected by the light projector. The coordinate input apparatus sets a first coordinate system based on a positional relationship between two light receptors constituting a first combination of the plurality of light receptors and a second coordinate system based on a positional relationship between two light receptors constituting a second combination that is different from the first combination, and converts a coordinate value of the specified position detected using the second coordinate system into a coordinate value in the first coordinate system..
Canon Kabushiki Kaisha


08/11/16
20160231658 

Electrophotographic photoreceptor and image forming apparatus


An electrophotographic photoreceptor includes: a conductive support; a photosensitive layer including at least an organic material; and a surface protective layer, wherein the photosensitive layer and the surface protective layer are provided on the conductive support, and the surface protective layer includes a photo-curable crosslinking monomer and a charge transport material including a mixture of a plurality of stereoisomers.. .
Konica Minolta, Inc.


08/11/16
20160231657 

Electrophotographic photoreceptor, process cartridge and image forming apparatus


According to an exemplary embodiment of the present invention, there is provided an electrophotographic photoreceptor having a conductive substrate, and a photosensitive layer arranged on the conductive substrate, wherein the photosensitive layer contains a charge-generating material, a charge-transporting material having a specific structure, a charge-transporting material having another specific structure, and at least one selected from a group consisting of a hindered phenol antioxidant having a molecular weight of 300 or more and a benzophenone uv absorbent.. .
Fuji Xerox Co., Ltd.


08/11/16
20160231323 

Protection of tcr signaling chains in cancer patients and enhancement of car-t cell therapy


Disclosed are means of protecting signaling integrity of t cells in cancer patients through reduction of neutrophil and other cellular induced oxidative stress. In one embodiment the fda approved drug mucomyst is administered at a concentration of 50-150 mg/kg to increase expression of t cell receptor (tcr)-zeta chain in patients with cancer.
Batu Biologics, Inc.


08/11/16
20160231316 

Nanovesicle comprising heterodimer g-protein coupled receptor, preparing nanovesicle, field effect transistor-based taste sensor comprising nanovesicle, and manufacturing taste sensor


The present invention relates to a nanovesicle comprising a heterodimeric g-protein coupled receptor, a method for preparing the nanovesicle, a field effect transistor-based taste sensor comprising the nanovesicle, and a method for manufacturing the taste sensor. The field effect transistor based taste sensor functionalized by the nanovesicle comprising the heterodimer g-protein coupled receptor according to the present invention has excellent sensitivity and selectivity and may highly specifically detect a sweet taste substance in real time, by using the heterodimeric g-protein coupled receptor and the nanovesicle comprising the same..
Seoul National University R&db Foundation


08/11/16
20160230155 

Modified sulfamidase and production thereof


Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal..
Swedish Orphan Biovitrum Ab (publ)


08/11/16
20160229918 

Tumor selective antibodies specific to oncofetal antigen/immature laminin receptor protein


Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the c terminal region of oncofetal antigen (ofa)/immature laminin receptor protein (ilrp), and which do not substantially cross-react with mature ofa/lrp. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy.
South Alabama Medical Science Foundation


08/11/16
20160229917 

Antagonist anti-il-7 receptor antibodies and methods


The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.
Rinat Neuroscience Corp.


08/11/16
20160229916 

High affinity antibodies to human il-6 receptor


A human antibody or an antigen-binding fragment which binds human il-6 receptor (hil-6r) with a kd of about 500 pm or less and blocks il-6 activity with an ic50 of 200 pm or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hil-6r with an affinity at least 2-fold higher relative to its binding monkey il-6r..
Regeneron Pharmaceuticals, Inc.


08/11/16
20160229914 

Method of treating a pathological syndrome


A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.. .

08/11/16
20160229896 

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses


A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific t cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (apc)-binding domain or a cd91 receptor-binding domain, located at the n-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to seq id no: 4, 2, 3, or 6, located at the c-terminus of the apc-binding domain or the cd91 receptor-binding domain; and (c) an antigen of a pathogen, located at the c-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of seq id no: 13; and (e) an endoplasmic reticulum retention sequence, located at the c-terminus of the fusion protein..
Thevax Genetics Vaccine Co., Ltd.


08/11/16
20160229857 

Substituted pyrrolo[2,3-d]dipyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors


Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (fr) of cancerous tumor cells and inhibit purine synthesis and hence, dna synthesis..
Duquesne University Of The Holy Ghost


08/11/16
20160229850 

Trka kinase inhibitors, compositions and methods thereof


The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.


08/11/16
20160229849 

Quinolone derivatives as fibroblast growth factor receptor inhibitors


Compounds that are fibroblast growth factor inhibitors (fgfr) and are therefore useful for the treatment of diseases treatable by inhibition of fgfr are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Principia Biopharma, Inc.


08/11/16
20160229813 

Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

08/11/16
20160229811 

Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer


The present disclosure provides tetra-substituted cyclobutane inhibitors of androgen receptor action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.. .
Duke University


08/11/16
20160229804 

Trka kinase inhibitors, compositions and methods thereof


The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.


08/11/16
20160229802 

C5ar antagonists


Compounds are provided that are modulators of the c5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of c5a receptors..
Chemocentryx, Inc.


08/11/16
20160228589 

Methods and compositions for imaging disorders using polyspecific agents


The present invention provides compositions and methods for detecting and/or monitoring a disease state with polyspecific imaging agents. In a particular embodiment, provided methods may be used to assess efficacy of anti-receptor tyrosine kinase and/or anti-cancer treatments.
Sloan-kettering Institute For Cancer Research


08/11/16
20160228573 

Liposome encapsulated affinity drug


The disclosure provides a liposomal antifolate composition comprising a liposome including an interior space, a bioactive antifolate agent disposed within said interior space, a steric stabilizer attached to an exterior of the liposome, and a targeting moiety comprising a protein with specific affinity for at least one folate receptor, said targeting moiety attached to at least one of the steric stabilizer and the exterior of the liposome.. .
L.e.a.f. Holdings Group Llc


08/11/16
20160228547 

Chimeric antigen receptor targeting of tumor endothelium


Disclosed are methods, protocols, and compositions of matter related to utilization of chimeric antigen receptor (car) expressing cells for the targeting of tumor endothelium utilizing chimeric antigen receptor expressing stem cells. In one embodiment tumor endothelium specific antigens are utilized as targets of the antigen binding domain of a car, which is attached to an extracellular hinge domain, a domain that transverses the t cell membrane and an intracellular domain associated with t cell signaling.
Batu Biologics, Inc.


08/11/16
20160228512 

Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn-lambda ligands engage a novel receptor ifn-lambdar1 (crf2-12) and il-10r2 (crf2-4) for signaling and induction of biological activities


A novel ifn-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated inf-λ1, ifn-λ2, ifn-λ3, based inter alia, in their ability to induce antiviral protection.
Rutgers, The State University Of New Jersey


08/11/16
20160228495 

Targeting the egfr-sglt1 interaction for cancer therapy


A compound can destabilize an epidermal growth factor receptor (egfr) protein and a sodium/glucose co-transporter 1 (sglt 1) protein. In one embodiment, the compound is a peptide derived from the interacting domain of egfr.
The University Of Houston System


08/11/16
20160228452 

Treatment of metabolic diseases by inhibtion of htr2a or htr3


The present invention relates to a method for preventing or treating a metabolic disease, which comprises inhibiting htr2a (5-hydroxytryptamine 2a receptor) or htr3a (5-hydroxytryptamine 3a receptor). The inhibition of htr3a leads to various advantageous efficacies for therapy of metabolic diseases, including resistance to obesity, decrease of lipid droplet size, increase of expression levels of thermogenic genes, increase of metabolic activities, increase of insulin sensitivity and decrease of ldl cholesterol and leptin..
Korea Advanced Institute Of Science And Technology


08/11/16
20160228450 

Novel glp-1 receptor modulators


Where a, b, c, y1, y2, z, r1, r2, r3, r4, r5, w1, n, p and q are as defined herein.. .

08/11/16
20160228446 

Combination drug therapy


A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-di-methyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt or solvate thereof, with a pi3kβ inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1h-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of androgen receptor and/or pi3kβ is beneficial, e.g., cancer.. .
Glaxosmithkline Llcc


08/11/16
20160228439 

Method and pharmaceutical composition for use in the treatment of epilepsy


The present invention relates to a compound which is an antagonist of the gluk2/gluk5 receptor or an inhibitor of the gluk2/gluk5 receptor expression for use in the treatment or the prevention of epilepsy.. .
Centre National De La Recherche Scientifique (cnrs)


08/11/16
20160228431 

Methods for treating cancer with trka receptor tyrosine kinase antagonists


The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.. .

08/11/16
20160228426 

Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients


Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of rs-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine h-1-, h-2- and h-4-receptor inhibitors.
Bridge Pharma, Inc.


08/11/16
20160228413 

Chemokine receptor binding heterocyclic compounds with enhanced efficacy


The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains n and optionally contains additional rings. The compounds bind to chemokine receptors, including cxcr4 and ccr5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (hiv)..
Genzyme Corporation


08/11/16
20160228410 

An anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells


The present invention provides the compound ormeloxifene [3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy)phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like c/ebpα and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (gcsfr).
Council Of Scienticfic & Industrial Research


08/11/16
20160228407 

Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators


The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.. .
Allergan, Inc.


08/04/16
20160226309 

Wireless power transmission via inductive coupling using di/dt as the magnetic modulation scheme


The disclosed couplers operate in a “near field” mode, meaning energy, whether used to transmit data or power, is transferred through magnetic induction using a ∂i/∂t circuit (meaning a change in current over a change in time), such as by using inductive transmission and receive coils in which resistors and/or other components such as diodes are placed into series and/or in parallel with the coils and used to control the shape of the pulse, e.g. Its voltage and/or frequency.
Oceaneering International, Inc.


08/04/16
20160223976 

Electrophotographic photoreceptor, image forming apparatus, and image forming process


An electrophotographic photoreceptor includes an intermediate layer, a photosensitive layer, and a surface protective layer, deposited in this order on an electroconductive support. The surface protective layer includes a resin and a p-type semiconductor microparticle contained in the resin.
Konica Minolta, Inc.


08/04/16
20160223925 

Cylindrical support for electrophotographic photoreceptor, electrophotographic photoreceptor, process cartridge, and image forming apparatus


A cylindrical support for an electrophotographic photoreceptor includes an aluminum alloy including si: 0.4% by weight to 0.8% by weight, fe: 0.7% by weight or less, cu: 0.15% by weight to 0.4% by weight, mn: 0.15% by weight or less, mg: 0.8% by weight to 1.2% by weight, cr: 0.04% by weight to 0.35% by weight, zn: 0.25% by weight or less, ti: 0.15% by weight or less, and a balance: aluminum and impurities, wherein an average area of crystal grains of the aluminum alloy is from 3.0 μm2 to 100 μm2.. .
Fuji Xerox Co., Ltd.


08/04/16
20160223572 

Cancer marker and therapeutic target


Chemokine receptor ccr4 and its ligands ccl17 and ccl22 are used as markers for the identification and/or staging of cancer. The level of ccr4, ccl17 and ccl22 are found to increase during malignant tumour progression.
Cancer Research Technology Ltd.


08/04/16
20160222945 

Wind power generation apparatus


Provided is a wind power generation apparatus including a wind turbine blade that has a blade body and a receptor mounted on a tip of the blade body. The receptor includes a solid blade outer portion that is positioned on an outside of a tip opening portion of the blade body and a blade inner portion that is positioned on an inside of the tip opening portion.
Hitachi, Ltd.


08/04/16
20160222413 

Subgroup b recombinant human adenovirus vector, and methods for constructing and for using the same


A method for reconstructing a replication-selective oncolytic adenovirus using a subgroup b recombinant human adenovirus vector ad11-5ep. The method includes: 1) deleting e1a cr2 gene and/or anti-apoptotic gene e1b 21k that is necessary for viability of an adenovirus in normal cells but not necessary in tumor cells; 2) inserting a tumor-specific promoter to drive the expression of e1a gene; 3) re-directing a cellular tropism of ad11-5ep according to receptors on a tumor cell surface; or 4) allowing adenovirus to selectively replicate in tumor cells..
Beijing Bio-targeting Therapeutics Technology Inc.


08/04/16
20160222123 

Method treating neuronal tissue inflammation using an il-31ra monoclonal antibody


Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof.
Zymogenetics, Inc.


08/04/16
20160222112 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222111 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222110 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222109 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222108 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222084 

Compositions comprising d-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies


Compositions are disclosed that include d-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a g-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease condition or disorder, and the autoantibody is capable of binding to a specific epitope of the g-protein coupled receptor.
The Board Of Regents Of The University Of Oklahoma


08/04/16
20160222080 

Multiple target t cell receptor


The present invention is directed to a functional t cell receptor (tcr) fusion protein (tfp) recognizing and binding to at least one mhc-presented epitope, and containing at least one amino acid sequence recognizing and binding an antigen. The present invention is further directed to an isolated nucleic acid molecule encoding the same, a t cell expressing said tfp, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen..
Max-delbrück-centrum Für Molekulare Medizin


08/04/16
20160222074 

Alpha-fetoprotein "ring and tail" peptides


The invention relates to compounds that are analogs of a cyclic peptide, cyclo[ektovnogn], afpep, that has anti-estrotrophic activity. The analogs of the invention include peptides and peptidomimetics that inhibit estrogen receptor-dependent cell proliferation.
Albany Medical College


08/04/16
20160222025 

Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death


The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
Helmholtz Zentrum MÜnchen Deutsches Forschungszentrum FÜr Gesundheit Und Umwelt (gmbh)


08/04/16
20160222024 

S-enantiomer of tetracyclic indole derivative as pbr ligands


The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (tspo, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known tspo-binding radiotracers.
Ge Healthcare Limited


08/04/16
20160222004 

Thiazole and oxazole-substituted arylamides as p2x3 and p2x2/3 antagonists


And x, r2, r3, r4, r5, r6, ra and rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a p2x3 and/or a p2x2/3 receptor antagonist and methods of making the subject compounds..





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.7631

4632

1 - 1 - 102